Barchart on Facebook
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Novavax Inc (NVAX)

Novavax Inc (NVAX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,001,425
  • Shares Outstanding, K 63,660
  • Annual Sales, $ 18,660 K
  • Annual Income, $ -132,690 K
  • 60-Month Beta 1.63
  • Price/Sales 349.99
  • Price/Cash Flow N/A
  • Price/Book 59.07
Trade NVAX with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -1.90
  • Number of Estimates 3
  • High Estimate 0.10
  • Low Estimate -4.74
  • Prior Year -1.13
  • Growth Rate Est. (year over year) -68.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
76.59 +64.10%
on 11/10/20
132.00 -4.78%
on 11/27/20
+36.10 (+40.29%)
since 10/27/20
3-Month
76.59 +64.10%
on 11/10/20
132.00 -4.78%
on 11/27/20
+18.34 (+17.08%)
since 08/27/20
52-Week
3.65 +3,341.86%
on 01/13/20
189.40 -33.64%
on 08/05/20
+121.75 (+3,090.10%)
since 11/27/19

Most Recent Stories

More News
Thinking about trading options or stock in Novavax, Tesla, AstraZeneca, Apple, or Moderna?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NVAX, TSLA, AZN, AAPL, and MRNA.

AAPL : 116.59 (+0.48%)
AZN : 52.61 (+0.02%)
MRNA : 127.03 (+16.35%)
NVAX : 125.69 (+22.50%)
TSLA : 585.76 (+2.05%)
4 Biotechs Likely to Gain on Coronavirus Vaccine Efforts

In the race to develop a coronavirus vaccine, Pfizer and its partner BioNTech have a lead, closely followed by Moderna. However, four other biotechs, NVAX, TBIO, INO and VXRT, still hold potential to gain...

NVAX : 125.69 (+22.50%)
TBIO : 19.35 (+6.14%)
INO : 12.26 (+18.00%)
VXRT : 7.03 (+9.84%)
Altimmune (ALT) Files IND for Phase I Study on Coronavirus Vaccine

Altimmune (ALT) files a regulatory application to begin a phase I study in the United States on AdCOVID, its intranasal COVID-19 vaccine candidate. Stock rises.

NVAX : 125.69 (+22.50%)
ALT : 10.52 (+4.26%)
VXRT : 7.03 (+9.84%)
CVAC : 86.00 (+5.15%)
Novavax to Participate in Upcoming Conferences

Novavax Inc. (Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will participate in two upcoming investor conferences....

NVAX : 125.69 (+22.50%)
After Yesterday's Rally of 6.89% Shares Could Potentially Pullback

Novavax Inc (NASDAQ:NVAX) traded in a range yesterday that spanned from a low of $95.00 to a high of $102.88. Yesterday, the shares gained 6.9%, which took the trading range above the 3-day high of $98.39...

NVAX : 125.69 (+22.50%)
Diagnostic Capabilities Remain of Utmost Importance as Cases Surge Worldwide

, /PRNewswire/ -- As of earlier this week, the U.S. has reported more than 12.4 million cases and over 257,600 deaths, . Dr. , the National Institute of Allergy and Infectious Diseases, has also...

CYDY : 2.6600 (-0.37%)
AYTU : 0.9198 (+2.20%)
NVAX : 125.69 (+22.50%)
IBIO : 1.5100 (+3.42%)
COVID-19 Vaccine & Therapeutics Clinical Trial Analysis Report 2020

The "COVID-19 Vaccine & Therapeutics Clinical Trial Analysis 2020" report has been added to ResearchAndMarkets.com's offering.

HTBX : 1.1400 (+3.64%)
INO : 12.26 (+18.00%)
NVAX : 125.69 (+22.50%)
Diagnostic Testing Remains Vital as New Treatment Breakthroughs are Announced

, /PRNewswire/ -- Researchers seem to be getting closer and closer to a vaccine to properly fight the current pandemic. Yesterday, Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA)...

NVAX : 125.69 (+22.50%)
FLIR : 39.13 (-2.10%)
TOMDF : 0.0550 (-4.35%)
PFE : 37.23 (+1.92%)
BNTX : 109.99 (+4.79%)
AZN : 52.61 (+0.02%)
Vaccine Hopes Push Markets To Frothy Levels: Stocks To Watch

Vaccine Hopes Push Markets To Frothy Levels: Stocks To Watch

SPY : 363.67 (+0.28%)
SPLK : 204.03 (+2.60%)
PFE : 37.23 (+1.92%)
NVAX : 125.69 (+22.50%)
MRNA : 127.03 (+16.35%)
JNJ : 144.00 (+0.22%)
ETSY : 160.55 (+10.66%)
DOCU : 226.87 (+1.21%)
CRM : 247.63 (+0.33%)
BABA : 276.48 (-0.45%)
AZN : 52.61 (+0.02%)
AMZN : 3,195.34 (+0.32%)
Should you invest in Nio, Boeing, Novavax, Bank of America, or Li Auto?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIO, BA, NVAX, BAC, and LI.

LI : 39.48 (-3.05%)
NVAX : 125.69 (+22.50%)
BA : 216.50 (-0.51%)
BAC : 28.99 (-0.14%)
NIO : 54.00 (+0.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as...

See More

Key Turning Points

2nd Resistance Point 146.56
1st Resistance Point 136.13
Last Price 125.69
1st Support Level 111.13
2nd Support Level 96.56

See More

52-Week High 189.40
Last Price 125.69
Fibonacci 61.8% 118.44
Fibonacci 50% 96.53
Fibonacci 38.2% 74.61
52-Week Low 3.65

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar